YPL109C Antibody

What is YPL109C and why is it important for mitochondrial research?

YPL109C (renamed Cqd1) is an uncharacterized mitochondrial protein that has been identified as one of nine mitochondrial proteins harboring likely deleterious mutations. It is an integral inner mitochondrial membrane (IMM) protein that faces the intermembrane space (IMS) . YPL109C belongs to the UbiB family of proteins, which are widespread and highly conserved across all domains of life. These proteins are essential for coenzyme Q (CoQ) biosynthesis and distribution within cells . Understanding YPL109C is crucial for research into mitochondrial function, particularly in relation to CoQ metabolism, which impacts cellular energy production and oxidative stress response.

What epitopes of YPL109C are commonly targeted for antibody production?

For YPL109C antibody production, researchers typically target conserved epitopes in the protein's structure that are accessible in its native conformation within the inner mitochondrial membrane. Since YPL109C is an integral membrane protein facing the intermembrane space , epitopes in hydrophilic domains that extend into the IMS are preferred targets. When developing antibodies against such membrane proteins, researchers often use peptide fragments corresponding to exposed regions or recombinant protein fragments that maintain proper folding to generate antibodies with optimal specificity and affinity.

How does YPL109C relate to human ADCK2 and what implications does this have for antibody cross-reactivity?

YPL109C appears to be functionally related to human ADCK2, as evidenced by complementation studies where yeast YPL109C mutants were transformed with vectors containing different versions of human ADCK2 . This functional relationship suggests evolutionary conservation between these proteins. For antibody development, this relationship is significant as it raises the possibility of cross-reactivity. Antibodies designed against conserved regions might recognize both yeast YPL109C and human ADCK2, which could be either advantageous for comparative studies or problematic when absolute specificity is required. Researchers should validate antibody specificity through multiple techniques including Western blotting against both yeast and human samples to confirm or rule out cross-reactivity.

What are the optimal fixation and permeabilization methods for immunolocalization of YPL109C in yeast cells?

For effective immunolocalization of YPL109C in yeast cells, a combination of chemical fixation and enzymatic cell wall digestion is optimal. Since YPL109C is an integral inner mitochondrial membrane protein , researchers should:

• Fix yeast cells with 4% paraformaldehyde for 30 minutes at room temperature to preserve protein structure

• Treat with zymolyase to digest the cell wall while maintaining membrane integrity

• Permeabilize with a gentle detergent like 0.1% Triton X-100 to allow antibody access to mitochondrial membranes

• Block with 3-5% BSA to reduce non-specific binding

• Apply YPL109C primary antibody (typically 1:100-1:500 dilution)

• Use fluorophore-conjugated secondary antibodies for detection

Co-staining with mitochondrial markers like TOM20 (as used in ADCK2 studies ) can help confirm mitochondrial localization. This approach is preferable to harsher permeabilization methods that might disrupt mitochondrial membrane structure and alter epitope accessibility.

What protocols are most effective for isolating intact YPL109C protein for antibody validation?

For isolating intact YPL109C protein while maintaining its native conformation for antibody validation, the SMALP (Styrene Maleic Acid Lipid Particle) method mentioned in search result is highly effective. This approach:

• Preserves the protein in its native lipid environment, maintaining structural integrity

• Solubilizes membrane proteins without harsh detergents that might denature epitopes

• Results in nano-sized lipid particles containing the target membrane protein

The protocol involves:

• Isolating mitochondria from yeast cells through differential centrifugation

• Treating mitochondrial fractions with SMA copolymer (2-3% w/v) for 2 hours at room temperature

• Removing insoluble material by ultracentrifugation (100,000 × g, 60 min)

• Purifying SMALPs containing YPL109C using affinity chromatography with tagged versions of the protein

This method provides properly folded YPL109C protein with preserved epitopes for comprehensive antibody validation through techniques like Western blotting, immunoprecipitation, and ELISA .

How can researchers optimize Western blot conditions for detecting YPL109C in different subcellular fractions?

For optimal Western blot detection of YPL109C across different subcellular fractions, researchers should implement a protocol that accounts for YPL109C's membrane association and potential post-translational modifications:

• Sample preparation:

  • Prepare whole cell lysates, mitochondrial fractions, and other subcellular components using gentle lysis buffers containing protease inhibitors

  • For membrane fractions, include 1% digitonin or 0.5% DDM to effectively solubilize membrane proteins without excessive denaturation

• Gel electrophoresis:

  • Use 10-12% SDS-PAGE gels to effectively separate proteins in the expected molecular weight range

  • Include a gradient gel option to accommodate potential oligomeric forms

• Transfer conditions:

  • Transfer at lower voltage (25V) for longer duration (16 hours) at 4°C to ensure complete transfer of membrane proteins

  • Use PVDF membranes with 0.45 μm pore size for optimal protein binding

• Antibody conditions:

  • Block with 5% non-fat dry milk in TBST for 1 hour

  • Incubate with primary YPL109C antibody (1:1000 dilution) overnight at 4°C

  • Use HRP-conjugated secondary antibodies with enhanced chemiluminescence detection

• Controls:

  • Include YPL109C knockout/mutant samples as negative controls

  • Use GFP-tagged YPL109C and GFP antibodies as positive controls, similar to approaches used in other studies with GFP nanobody constructs

This optimized protocol enables consistent and specific detection of YPL109C across different subcellular fractions while minimizing background and non-specific binding.

How can YPL109C antibodies be utilized in CoQ distribution studies within yeast cells?

YPL109C (Cqd1) has been implicated in regulating cellular CoQ distribution . To leverage YPL109C antibodies for studying this function, researchers can implement:

• Immunoprecipitation coupled with LC-MS analysis:

  • Use YPL109C antibodies conjugated to magnetic beads to pull down YPL109C protein complexes

  • Analyze co-precipitated lipids using LC-MS methods similar to those described in , employing:

    • An Acquity CSH C18 column (100 mm × 2.1 mm × 1.7 μm particle size)

    • Mobile phase A: 10 mM ammonium acetate and 250 μL/L acetic acid in ACN:H₂O (70:30, v/v)

    • Mobile phase B: IPA:ACN (90:10, v/v) with 10 mM ammonium acetate and 250 μL/L acetic acid

    • Q Exactive Orbitrap mass spectrometer detection

  • Quantify associated CoQ₆ species to determine how YPL109C influences CoQ binding and distribution

• Proximity labeling combined with immunodetection:

  • Express YPL109C fused to enzymes like BioID or APEX2

  • After activation and biotinylation of proximal proteins and lipids

  • Use YPL109C antibodies alongside streptavidin to map the spatial relationship between YPL109C and CoQ distribution sites

• Correlative light and electron microscopy:

  • Use gold-conjugated YPL109C antibodies for immunoelectron microscopy

  • Combine with fluorescent CoQ analogs to visualize the spatial relationship between YPL109C localization and CoQ distribution

These approaches provide complementary data on how YPL109C interacts with and influences CoQ distribution, offering insights into its mechanistic role in mitochondrial function.

What strategies can be employed to study the interaction between YPL109C and Ylr253w (Cqd2) using antibodies?

To study the interaction between YPL109C (Cqd1) and Ylr253w (Cqd2), which have been identified as reciprocal regulators , researchers can employ several antibody-based approaches:

• Co-immunoprecipitation with quantitative analysis:

  • Immunoprecipitate YPL109C using specific antibodies

  • Detect co-precipitated Ylr253w (Cqd2) using Ylr253w-specific antibodies

  • Perform reverse co-IP to confirm the interaction

  • Quantify the stoichiometry of the interaction using quantitative Western blotting with purified protein standards

• Proximity ligation assay (PLA):

  • Apply primary antibodies against both YPL109C and Ylr253w to fixed yeast cells

  • Use oligonucleotide-conjugated secondary antibodies that generate a signal only when the proteins are in close proximity (<40 nm)

  • Quantify interaction signals across different cellular conditions or mutant backgrounds

• FRET-based immunofluorescence:

  • Use fluorophore-conjugated antibodies against YPL109C and Ylr253w

  • Measure FRET efficiency as an indicator of protein-protein distance

  • Map interaction dynamics across different mitochondrial subcompartments

• Bimolecular Fluorescence Complementation (BiFC) validation:

  • Express split-fluorescent protein fusions to YPL109C and Ylr253w

  • Use antibodies to confirm proper expression and localization of the fusion proteins

  • Correlate BiFC signals with antibody-based quantification of protein levels

These comprehensive approaches provide multidimensional data on the YPL109C-Ylr253w interaction, including confirmation of physical association, spatial organization, and regulatory dynamics.

How can researchers establish quantitative assays for YPL109C expression levels in response to metabolic changes?

To quantitatively assess YPL109C expression levels in response to metabolic changes, researchers can implement:

• Quantitative Western blot analysis:

  • Culture yeast under various metabolic conditions (different carbon sources, oxidative stress)

  • Prepare standardized whole-cell lysates with precise protein quantification

  • Perform Western blots with YPL109C antibodies alongside loading controls

  • Include recombinant YPL109C protein standards at known concentrations (5-100 ng range)

  • Use digital imaging systems for precise densitometry

  • Calculate absolute YPL109C quantities per cell using the standard curve

• Flow cytometry with intracellular staining:

  • Fix and permeabilize yeast cells from different metabolic conditions

  • Stain with fluorophore-conjugated YPL109C antibodies or primary/secondary antibody combinations

  • Use calibration beads containing known quantities of fluorophore

  • Convert mean fluorescence intensity to molecules of equivalent soluble fluorophore (MESF)

  • Calculate the number of YPL109C molecules per cell

• Immunofluorescence microscopy with quantitative image analysis:

  • Prepare yeast cells from different metabolic conditions using standardized protocols

  • Perform immunofluorescence with YPL109C antibodies

  • Acquire images with identical exposure settings

  • Analyze using software like CellProfiler to measure integrated signal intensity

  • Correlate integrated intensity with protein amount using calibration standards

• ELISA-based quantification:

  • Develop a sandwich ELISA using two different YPL109C antibodies recognizing distinct epitopes

  • Generate a standard curve using purified recombinant YPL109C

  • Process samples from different metabolic conditions

  • Determine absolute concentration of YPL109C in each sample

These methods provide complementary approaches to reliably quantify YPL109C expression changes under different metabolic conditions, offering insights into its regulation and function.

What are common pitfalls in YPL109C antibody experiments and how can they be addressed?

Common pitfalls in YPL109C antibody experiments include:

• Non-specific binding and false positives:

  • Problem: YPL109C antibodies cross-reacting with other UbiB family proteins

  • Solution: Validate antibody specificity using YPL109C knockout yeast strains

  • Implementation: Include side-by-side Western blots or immunostaining of wild-type and YPL109C deletion strains to confirm signal specificity

• Poor signal in membrane fractions:

  • Problem: Insufficient solubilization of membrane-embedded YPL109C

  • Solution: Optimize membrane protein extraction using SMALP method mentioned in

  • Implementation: Compare different detergents (digitonin, DDM, Triton X-100) and solubilization times to determine optimal conditions

• Inconsistent immunoprecipitation results:

  • Problem: Variable efficiency in pulling down YPL109C complexes

  • Solution: Use a tagged version of YPL109C alongside antibody-based approaches

  • Implementation: Compare results from antibody-based IP with GFP-nanobody pulldown of GFP-tagged YPL109C

• Epitope masking in native complexes:

  • Problem: YPL109C epitopes becoming inaccessible when in protein complexes

  • Solution: Use multiple antibodies targeting different regions of YPL109C

  • Implementation: Develop and validate antibodies against N-terminal, C-terminal, and internal epitopes

• Fixation-induced artifacts in localization studies:

  • Problem: Altered mitochondrial morphology affecting YPL109C localization patterns

  • Solution: Compare multiple fixation protocols and live-cell imaging with tagged YPL109C

  • Implementation: Systematically compare paraformaldehyde, glutaraldehyde, and methanol fixation methods

By anticipating these common issues and implementing appropriate controls and optimization strategies, researchers can significantly improve the reliability of YPL109C antibody experiments.

How can researchers validate the specificity and sensitivity of YPL109C antibodies?

To comprehensively validate YPL109C antibodies, researchers should implement a multi-tiered approach:

• Genetic validation:

  • Test antibody signal in wild-type vs. YPL109C knockout strains

  • Examine signal in strains with varying YPL109C expression levels

  • Assess antibody performance in strains expressing tagged versions of YPL109C (similar to GFP-tagged constructs mentioned in )

• Biochemical validation:

  • Perform Western blots against purified recombinant YPL109C protein

  • Conduct peptide competition assays to confirm epitope specificity

  • Test cross-reactivity against related UbiB family proteins

  • Perform immunoprecipitation followed by mass spectrometry to confirm target identity

• Sensitivity assessment:

  • Generate standard curves using known quantities of recombinant YPL109C

  • Determine limits of detection and quantification in various sample types

  • Compare sensitivity across different application methods (Western blot, IF, ELISA)

• Application-specific validation:

  • For immunofluorescence: Compare antibody localization patterns with fluorescently tagged YPL109C

  • For ChIP applications: Validate enrichment at expected genomic loci

  • For immunoprecipitation: Confirm pull-down of known interaction partners like Ylr253w (Cqd2)

• Thermal shift assay validation:

  • Apply differential scanning fluorimetry methods similar to those described in

  • Use purified YPL109C protein with SYPRO® Orange Dye

  • Compare thermal stability profiles of free protein versus antibody-bound protein

How does research on YPL109C complement studies on human ADCK2, and what antibody strategies bridge these fields?

Research on yeast YPL109C provides fundamental insights applicable to human ADCK2 studies through evolutionary conservation of function. The complementary relationship is evidenced by studies showing yeast YPL109C mutants can be transformed with vectors containing human ADCK2 . To bridge these research areas:

• Epitope conservation analysis:

  • Identify conserved epitopes between YPL109C and human ADCK2

  • Develop antibodies against these conserved regions

  • Validate cross-reactivity and specificity in both yeast and human systems

• Parallel experimental approaches:

  • Apply similar immunolocalization techniques in both systems

  • Use ADCK2 antibodies with protocols like those for TOM20 co-staining mentioned in

  • Correlate mitochondrial morphology changes across species using standardized imaging

• Functional complementation studies:

  • Use YPL109C antibodies to quantify expression levels in yeast complementation studies

  • Measure protein levels in systems where human ADCK2 variants are expressed in YPL109C mutants

  • Develop quantitative Western blot protocols that work for both proteins

• Disease-relevant applications:

  • Apply YPL109C research findings to study ADCK2 haploinsufficiency in mitochondrial lipid oxidation

  • Develop antibody-based assays to measure the impact of ADCK2 mutations on protein stability

  • Use yeast models to test antibody-based therapeutic approaches before moving to human systems

This bidirectional research approach leverages evolutionary conservation to translate findings between yeast and human systems, with antibody tools serving as critical reagents for comparative studies.

What are key differences in experimental approaches when using YPL109C antibodies compared to antibodies against other UbiB family proteins?

When working with YPL109C antibodies compared to antibodies against other UbiB family proteins, researchers should consider several key differences in experimental approaches:

• Subcellular localization considerations:

  • YPL109C is an integral inner mitochondrial membrane protein facing the intermembrane space

  • Other UbiB proteins may have different submitochondrial localizations

  • Permeabilization protocols must be tailored to the specific localization of each protein

  • For YPL109C, selective membrane permeabilization with digitonin can help distinguish inner vs. outer membrane localization

• Solubilization requirements:

  • YPL109C requires SMALP or similar gentle solubilization methods

  • Other UbiB proteins may have different detergent sensitivities

  • Optimization of extraction conditions should be protein-specific

  • Consider using native PAGE for comparing oligomeric states across the family

• Functional assay integration:

  • YPL109C antibodies should be incorporated into CoQ distribution assays

  • For CoQ8 (another UbiB protein), antibodies would be used in CoQ biosynthesis assays

  • Assay development should reflect the specific biological role of each family member

  • Consider multiplex assays to examine functional relationships between family members

• Cross-reactivity management:

  • Due to sequence conservation among UbiB proteins, epitope selection is critical

  • For YPL109C, target unique regions not conserved in other family members

  • Validate specificity against recombinant versions of multiple UbiB proteins

  • Consider developing antibody panels that can distinguish between related family members

These tailored approaches ensure that antibody-based studies of YPL109C yield specific and biologically relevant results despite the challenges posed by protein family conservation.

How can researchers integrate YPL109C antibody data with mass spectrometry results for comprehensive protein interaction mapping?

To integrate YPL109C antibody-based data with mass spectrometry for comprehensive protein interaction mapping, researchers should:

• Implement sequential immunoprecipitation and MS workflow:

  • Use YPL109C antibodies for immunoprecipitation from mitochondrial fractions

  • Process samples for LC-MS/MS analysis using instrumentation similar to that described in

  • Analyze using both data-dependent acquisition (DDA) and data-independent acquisition (DIA)

  • Compare results against control IPs from YPL109C deletion strains

• Develop scoring systems for interaction confidence:

  • Calculate enrichment ratios for each identified protein

  • Apply statistical filters (p-value, FDR) to distinguish specific from non-specific interactions

  • Create interaction confidence scores incorporating data from multiple replicates

  • Validate top hits using reciprocal co-IP with antibodies against identified partners

• Conduct spatially-resolved interactome analysis:

  • Fractionate mitochondria into submitochondrial compartments

  • Perform YPL109C IP from each fraction

  • Map interaction networks unique to different mitochondrial sublocations

  • Correlate with immunofluorescence colocalization data

• Integrate with functional data:

  • Connect protein interactions with CoQ distribution phenotypes

  • Create network models incorporating quantitative CoQ measurements

  • Apply machine learning to identify patterns in combined datasets

  • Validate key interaction-function relationships through genetic approaches

This integrated approach creates a multidimensional view of YPL109C's functional role, connecting its physical interactions to biochemical functions in CoQ metabolism and distribution.

What statistical approaches are most appropriate for analyzing variability in YPL109C antibody-based quantification across experimental conditions?

For robust statistical analysis of YPL109C antibody-based quantification across experimental conditions, researchers should implement:

• Normalization strategies:

  • For Western blot data: Normalize YPL109C signal to stable reference proteins (e.g., actin, VDAC)

  • For immunofluorescence: Use ratio metrics against mitochondrial mass markers

  • For flow cytometry: Apply fluorescence intensity calibration with standard beads

  • For ELISA: Include standard curves on each plate and calculate inter-plate normalization factors

• Appropriate statistical tests:

  • For normally distributed data: Apply parametric tests like ANOVA with Tukey's post-hoc comparisons (as used in )

  • For non-normally distributed data: Use non-parametric alternatives like Kruskal-Wallis with appropriate post-hoc tests

  • Always check data normality using Shapiro-Wilk test (as done in )

  • Report appropriate effect sizes alongside p-values

• Variance component analysis:

  • Decompose sources of variation (biological vs. technical)

  • Implement mixed-effects models to account for batch effects

  • Calculate intra-assay and inter-assay coefficients of variation

  • Determine minimum sample sizes needed for desired statistical power

• Advanced computational approaches:

  • Use bootstrapping for robust confidence interval estimation

  • Apply Bayesian statistical frameworks for complex experimental designs

  • Implement ANCOVA when controlling for covariates

  • Consider machine learning for pattern recognition in complex datasets

How should researchers approach data integration when combining YPL109C antibody results with genetic interaction screens and metabolomic analyses?

When integrating YPL109C antibody data with genetic interaction screens and metabolomic analyses, researchers should implement a systematic multi-omics approach:

• Data normalization and transformation:

  • Standardize YPL109C antibody quantification data using appropriate controls

  • Transform genetic interaction scores for compatibility with protein abundance data

  • Process metabolomic data using methods described in , including:

    • Targeted analysis of CoQ metabolites

    • Normalization to internal standards

    • Log transformation of metabolite concentrations

• Correlation analysis framework:

  • Calculate Pearson or Spearman correlations between:

    • YPL109C protein levels and genetic interaction scores

    • YPL109C levels and CoQ6/CoQ8 concentrations

    • Genetic interactions and metabolite profiles

  • Visualize correlation networks to identify functional clusters

• Integrative computational modeling:

  • Develop mathematical models incorporating all data types

  • Use approaches like Bayesian network analysis

  • Apply dimensionality reduction techniques (PCA, t-SNE) to visualize integrated datasets

  • Implement machine learning to predict functional relationships

• Experimental validation pipeline:

  • Design targeted experiments to test predictions from integrated analysis

  • Use YPL109C antibodies to measure protein levels in genetic interaction mutants

  • Quantify metabolic changes in strains with altered YPL109C levels

  • Iteratively refine models based on new experimental data

• Biological pathway mapping:

  • Connect YPL109C function to CoQ distribution pathways

  • Map genetic interactions onto known mitochondrial processes

  • Identify regulatory relationships between YPL109C and metabolic enzymes

  • Create comprehensive pathway models incorporating protein levels, genetic effects, and metabolite changes

This systematic integration approach transforms disparate data types into a coherent understanding of YPL109C's functional role in mitochondrial biology and CoQ metabolism.

What emerging antibody technologies might enhance YPL109C research in the next five years?

Several emerging antibody technologies hold significant promise for advancing YPL109C research:

• Single-domain antibodies and nanobodies:

  • Smaller size (15-25 kDa) allows better penetration of mitochondrial membranes

  • Can access epitopes in confined spaces like the intermembrane space where YPL109C resides

  • May be expressed intracellularly as "intrabodies" for live cell studies

  • Similar to GFP nanobody approaches already being used but with direct targeting of YPL109C

• Proximity-labeling antibody conjugates:

  • YPL109C antibodies conjugated to enzymes like APEX2, BioID, or TurboID

  • Allow spatially-resolved proteomic mapping around YPL109C

  • Can identify transient interactions missed by traditional co-IP approaches

  • Enable temporal studies of the YPL109C interaction network

• Split-epitope reconstitution systems:

  • Based on principles similar to chimeric scFv-IgG Fc approaches

  • Detect protein-protein interactions involving YPL109C in situ

  • Provide spatial information about YPL109C complexes

  • Generate signals only when target complexes form

• Quantitative multiplex imaging antibodies:

  • Simultaneous visualization of YPL109C with multiple interaction partners

  • Based on oligonucleotide-conjugated antibodies (similar to DNA-PAINT)

  • Allow super-resolution mapping of YPL109C relative to other mitochondrial proteins

  • Enable quantitative stoichiometry measurements in native complexes

• Conformation-specific antibodies:

  • Recognize specific structural states of YPL109C

  • Distinguish between active/inactive or bound/unbound states

  • Allow dynamic monitoring of YPL109C functional states

  • Provide mechanistic insights into CoQ distribution regulation

These emerging technologies will significantly enhance our ability to study YPL109C's localization, interactions, and functions with unprecedented spatial and temporal resolution.

How might developing antibodies against post-translational modifications of YPL109C advance understanding of its regulation?

Developing antibodies against post-translational modifications (PTMs) of YPL109C would provide crucial insights into its regulation:

• Phosphorylation-specific antibodies:

  • YPL109C, as a UbiB family protein, may undergo regulatory phosphorylation similar to COQ8's ATPase activity regulation

  • Phospho-specific antibodies could:

    • Track activation/inactivation cycles

    • Identify specific regulatory kinases

    • Monitor responses to metabolic changes

    • Map phosphorylation dynamics across different growth conditions

• Ubiquitination/SUMOylation detection:

  • Antibodies recognizing ubiquitinated or SUMOylated YPL109C could:

    • Reveal protein turnover mechanisms

    • Identify conditions triggering degradation

    • Connect to mitochondrial quality control pathways

    • Quantify modification stoichiometry under stress conditions

• Oxidative modification monitoring:

  • Given YPL109C's mitochondrial localization, oxidative modifications are likely

  • Antibodies against oxidized forms could:

    • Serve as markers of mitochondrial oxidative stress

    • Connect redox state to functional changes

    • Track modification reversibility

    • Identify protective mechanisms

• Acetylation status assessment:

  • Mitochondrial proteins are frequently regulated by acetylation

  • Acetylation-specific antibodies would:

    • Connect YPL109C to NAD+-dependent pathways

    • Reveal links to metabolic state

    • Identify regulatory deacetylases

    • Track modification dynamics during metabolic adaptation

• Methodological implementation:

  • Combine PTM-specific antibodies with quantitative proteomics

  • Develop multiplexed detection of multiple PTMs

  • Create temporal maps of modification sequences

  • Correlate modifications with CoQ distribution changes

This comprehensive PTM analysis would transform our understanding of YPL109C from a static protein to a dynamically regulated component of mitochondrial CoQ metabolism, revealing new therapeutic targets for mitochondrial diseases.